BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maggs JR, Chapman RW. An update on primary sclerosing cholangitis: . Current Opinion in Gastroenterology 2008;24:377-83. [DOI: 10.1097/mog.0b013e3282f9e239] [Cited by in Crossref: 86] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Eksteen B, Bowlus CL, Montano-Loza AJ, Lefebvre E, Fischer L, Vig P, Martins EB, Ahmad J, Yimam KK, Pockros PJ, Feld JJ, Minuk G, Levy C. Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study. Hepatol Commun 2021;5:478-90. [PMID: 33681680 DOI: 10.1002/hep4.1619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
3 Steenstraten IC, Sebib Korkmaz K, Trivedi PJ, Inderson A, van Hoek B, Rodriguez Girondo MDM, Maljaars PWJ. Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Aliment Pharmacol Ther. 2019;49:636-643. [PMID: 30740723 DOI: 10.1111/apt.15148] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
4 Seo N, Kim SY, Lee SS, Byun JH, Kim JH, Kim HJ, Lee MG. Sclerosing Cholangitis: Clinicopathologic Features, Imaging Spectrum, and Systemic Approach to Differential Diagnosis. Korean J Radiol 2016;17:25-38. [PMID: 26798213 DOI: 10.3348/kjr.2016.17.1.25] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
5 Saadi M, Yu C, Othman MO. A Review of the Challenges Associated with the Diagnosis and Therapy of Primary Sclerosing Cholangitis. J Clin Transl Hepatol 2014;2:45-52. [PMID: 26357617 DOI: 10.14218/JCTH.2013.00021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
6 Patil SA, Cross RK. Update in the management of extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2013;15:314. [PMID: 23371321 DOI: 10.1007/s11894-013-0314-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
7 Gossard AA. Care of the cholestatic patient. Clin Liver Dis 2013;17:331-44. [PMID: 23540506 DOI: 10.1016/j.cld.2012.11.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
8 Eaton JE, Talwalkar JA. Primary Sclerosing Cholangitis: Current and Future Management Strategies. Curr Hepat Rep 2013;12:28-36. [PMID: 23682242 DOI: 10.1007/s11901-012-0155-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
9 Lorenzoni PJ, Scola RH, Kay CS, Muzzillo DA, Werneck LC. Coexistence of primary sclerosing cholangitis in a patient with myasthenia gravis. Ann Indian Acad Neurol. 2011;14:316-318. [PMID: 22346028 DOI: 10.4103/0972-2327.91966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Barnabas A, Chapman RW. Primary sclerosing cholangitis: is any treatment worthwhile? Curr Gastroenterol Rep 2012;14:17-24. [PMID: 22124849 DOI: 10.1007/s11894-011-0230-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
11 Siddique A, Kowdley KV. Approach to a patient with elevated serum alkaline phosphatase. Clin Liver Dis. 2012;16:199-229. [PMID: 22541695 DOI: 10.1016/j.cld.2012.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
12 Wong GL, Wong VW. Medical therapy for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011;34:1135-6; discussion 1136-7. [PMID: 21981734 DOI: 10.1111/j.1365-2036.2011.04845.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Arenas-Gamboa AM, Bearss JJ, Hubbard GB, Porter BF, Owston MA, Dick EJ Jr. Sclerosing cholangitis in baboons (Papio spp) resembling primary sclerosing cholangitis of humans. Vet Pathol 2012;49:524-7. [PMID: 21934101 DOI: 10.1177/0300985811419532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Chapman R. Genome-wide association studies in primary sclerosing cholangitis: still more questions than answers? Hepatology 2011;53:2133-5. [PMID: 21618262 DOI: 10.1002/hep.24333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Heimbach JK, Sanchez W, Rosen CB, Gores GJ. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford). 2011;13:356-360. [PMID: 21492336 DOI: 10.1111/j.1477-2574.2011.00298.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 173] [Article Influence: 12.7] [Reference Citation Analysis]
16 Chapman RW. Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC? Nat Rev Gastroenterol Hepatol 2010;7:74-5. [PMID: 20134486 DOI: 10.1038/nrgastro.2009.235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ; American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-78. [PMID: 20101749 DOI: 10.1002/hep.23294] [Cited by in Crossref: 832] [Cited by in F6Publishing: 731] [Article Influence: 69.3] [Reference Citation Analysis]
18 Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? Hepatology 2009;50:671-3. [PMID: 19714717 DOI: 10.1002/hep.23174] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
19 Aytekin C, Dogu F, Tanir G, Guloglu D, Santisteban I, Hershfield MS, Ikinciogullari A. Purine nucleoside phosphorylase deficiency with fatal course in two sisters. Eur J Pediatr 2010;169:311-4. [PMID: 19657670 DOI: 10.1007/s00431-009-1029-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
20 Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol. 2009;6:297-305. [PMID: 19404270 DOI: 10.1038/nrgastro.2009.44] [Cited by in Crossref: 200] [Cited by in F6Publishing: 196] [Article Influence: 15.4] [Reference Citation Analysis]
21 Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol. 2009;6:297-305. [PMID: 19404270 DOI: 10.1038/nrgastro.2009.44.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Chuang YH, Lan RY, Gershwin ME. The immunopathology of human biliary cell epithelium. Semin Immunopathol. 2009;31:323-331. [PMID: 19533127 DOI: 10.1007/s00281-009-0172-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
23 Glaser SS, Alpini G. Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis. Hepatology 2009;49:1795-7. [PMID: 19475683 DOI: 10.1002/hep.22969] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]